Tanzania

Global Campaign to End Fistula

The Global Campaign to End Fistula seeks to reduce the prevalence of fistula in developing countries.

Global Alliance to Eliminate Lymphatic Filariasis (GAELF)

The Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was created to eliminate one of the world's leading causes of disability and disfigurement as a public health problem by the year 2020. An estimated 120 million people in at least 80 countries of the world suffer from the disease, and one billion (20% of the world's population) are at risk of infection.

GlaxoSmithKline & Access to Malaria Care

GlaxoSmithKline offers its antimalarials at not-for-profit prices to public sector customers and not-for-profit organizations in 64 countries - all the Least Developed Countries and all of sub-Saharan Africa. All CCM projects fully funded by the Global Fund to Fight AIDS TB and Malaria are also eligible. GSK does not make a profit at these prices, but it does cover its costs, so it can sustain supply of these high-quality products for as long as they are needed. These prices apply to orders of any size and include insurance and freight costs.

GlaxoSmithKline - Other HIV/AIDS Capacity-Building Initiatives

The GlaxoSmithKline Foundation supports a range of HIV/AIDS-related programs around the world. Since 1998, the GSK France Foundation has supported 86 programs to improve healthcare through prevention, education and training in 14 developing countries. The GSK Foundation Canada also supports community programs in Africa, including AIDS Orphans Uganda, working with the African Medical Research Foundation (AMREF).

Computerized Training for Management of Childhood Diseases

Every year, almost 10 million children die before they reach their fifth birthday. Many of these deaths could be avoided if those children received timely and appropriate care. It is the goal of the World Health Organization (WHO) to reduce the infant and child mortality rate by two-thirds by 2015 (compared with 1990). One of the most promising instruments for achieving this goal is the Integrated Management of Childhood Diseases (IMCI), an approach to managing the most common diseases such as pneumonia, diarrhea, malaria, measles, or malnutrition.

Changing Diabetes in Children

The Changing Diabetes in Children program is part of Novo Nordisk's Access to Diabetes Care strategy and aims at improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes in least developed countries, via partnerships. It also contributes to the achievement of the UN Millennium Development Goals, especially Goal 4: Reduce child mortality and Goal 8: Develop a global partnership for development.

Cancer Awareness Leadership Initiative (CALI)

The objective of the Cancer Awareness Leadership Initiative (CALI) is to raise awareness and quantify the burden of cancer in the developing world, to help encourage capacity development by bringing disparate parties together to explore ways to collaborate on cancer treatment programs. For example, Novartis and the Global Health Council (GHC) collaborated with the African Organization for Research and Treatment in Cancer (AORTIC) to sponsor a medical education module during an AORTIC conference in Dar-es-Salaam, Tanzania, in 2009.

Bristol-Myers Squibb's Secure The Future Children's Clinics & Pediatric AIDS Corps

Bristol-Myers Squibb's Secure The Future initiative (see HIV/AIDS Capacity Building), in partnership with Baylor College of Medicine, Houston, Texas, USA, funded the first clinical center in Africa for children and families with HIV/AIDS, located in Botswana. This center now has more than 1,500 children under treatment. Additional children's clinical centers have now been opened in Lesotho, Swaziland and Uganda, and two more are being built in Tanzania and Kenya.

Bristol-Myers Squibb's Secure The Future

Secure The Future is a comprehensive initiative to fight HIV/AIDS in sub-Saharan Africa, sponsored by Bristol-Myers Squibb and the Bristol-Myers Squibb Foundation. It combines medical treatment and care, access to antiretroviral medicines, with research, social support with community education, and training for health care professionals with new facilities and infrastructure investments in remote areas of sub-Saharan Africa where resources are extremely limited.

Boehringer Ingelheim Access

Boehringer Ingelheim offers its product Viramune® for single-dose use in the prevention of mother-to-child transmission for free and/or reduced prices.

Pages